In this minireview, we focus on advances in our knowledge of the human erythrocyte proteome and interactome that have occurred since our seminal review on the topic published in 2007. As will be explained, the number of unique proteins has grown from 751 in 2007 to 2289 as of today. We describe how proteomics and interactomics tools have been used to probe critical protein changes in disorders impacting the blood. The primary example used is the work done on sickle cell disease where biomarkers of severity have been identified, protein changes in the erythrocyte membranes identified, pharmacoproteomic impact of hydroxyurea studied and interactomics used to identify erythrocyte protein changes that are predicted to have the greatest impact on protein interaction networks.
GoodmanSRKurdiaAAmmannLKakhniashviliDDaescuO. The human red blood cell proteome and interactome. Exp Biol Med2007; 232(11): 1391–408.
2.
LowTYSeowTKChungMCM. Separation of human erythrocyte membrane associated proteins with one-dimensional and two-dimensional gel electrophoresis followed by identification with matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Proteomics2002; 2(9): 1229–39.
3.
KakhniashviliDGBullaLAJrGoodmanSR. The human erythrocyte proteome: Analysis by ion trap mass spectrometry. Mol Cell Proteomics2004; 3(5): 501–9.
4.
TyanYJongSLiaoJ. Proteomic profiling of erythrocyte proteins by proteolytic digestion chip and identification using two-dimensional electrospray ionization tandem mass spectrometry. J Proteome Res2005; 4(3): 748–57.
5.
PasiniEMKirkegaardMMortensenPLutzHUThomasAWMannM. In-depth analysis of the membrane and cytosolic proteome of red blood cells. Blood2006; 108(3): 791–801.
6.
BoschettiERighettiPG. Hexapeptide combinatorial ligand libraries: The march for the detection of the low-abundance proteome continues. BioTechniques2008; 44(5): 663–5.
7.
AlexandreBM. Proteomic mining of the red blood cell: Focus on the membrane proteome. Expert Rev Proteomics2010; 7(2): 165–8.
8.
LionNTissotJ. Application of proteomics to hematology: The revolution is starting. Expert Rev Proteomics2008; 5(3): 375–9.
9.
LiumbrunoGD'AmiciGMGrazziniGZollaL. Transfusion medicine in the era of proteomics. J Proteomics2008; 71(1): 34–45.
10.
ZollaL. Proteomics and transfusion medicine. Blood Transfus2008; 6(2): 67–9.
11.
BoschettiERighettiPG. The art of observing rare protein species in proteomes with peptide ligand libraries. Proteomics2009; 9(6): 1492–510.
12.
D'AlessandroARighettiPGZollaL. The red blood cell proteome and interactome: An update. J Proteome Res2010; 9(1): 144–63.
13.
LiumbrunoGD'AlessandroAGrazziniGZollaL. How has proteomics informed transfusion biology so far?Crit Rev Oncol2010; 76(3): 153–72.
PasiniEMLutzHUMannMThomasAW. Red blood cell (RBC) membrane proteomics – Part I: Proteomics and RBC physiology. J Proteomics2010; 73(3): 403–20.
16.
PasiniEMLutzHUMannMThomasAW. Red blood cell (RBC) membrane proteomics – Part II: Comparative proteomics and RBC patho-physiology. J Proteomics2010; 73(3): 421–35.
17.
NeelamSKakhniashviliDGWilkensSLeveneSDGoodmanSR. Functional 20S proteasomes in mature human red blood cells. Exp Biol Med2011; 236(5): 580–91.
18.
BachiASimóCRestucciaU. Performance of combinatorial peptide libraries in capturing the low-abundance proteome of red blood cells. 2. Behavior of resins containing individual amino acids. Anal Chem2008; 80(10): 3557–65.
19.
BoschettiERighettiPG. The ProteoMiner in the proteomic arena: A non-depleting tool for discovering low-abundance species. J Proteomics2008; 71(3): 255–64.
20.
Roux-DalvaiFde PeredoAGSimóC. Extensive analysis of the cytoplasmic proteome of human erythrocytes using the peptide ligand library technology and advanced mass spectrometry. Mol Cell Proteomics2008; 7(11): 2254–69.
21.
SimóCBachiACattaneoA. Performance of combinatorial peptide libraries in capturing the low-abundance proteome of red blood cells. 1. Behavior of mono- to hexapeptides. Anal Chem2008; 80(10): 3547–56.
22.
BosmanGJCGMLasonderELutenM. The proteome of red cell membranes and vesicles during storage in blood bank conditions. Transfusion2008; 48(5): 827–35.
23.
BosmanGJCGMLasonderEGroenen-DöppYAMWillekensFLAWerreJMNovotnýVMJ. Comparative proteomics of erythrocyte aging in vivo and in vitro. J Proteomics2010; 73(3): 396–402.
24.
D'AmiciGMRinalducciSZollaL. Proteomic analysis of RBC membrane protein degradation during blood storage. J Proteome Res2007; 6(8): 3242–55.
25.
HelbigAOHeckAJRSlijperM. Exploring the membrane proteome-challenges and analytical strategies. J Proteomics2010; 73(5): 868–78.
26.
van GestelRAvan SolingeWWvan der ToornHWP. Quantitative erythrocyte membrane proteome analysis with blue-Native/SDS PAGE. J Proteomics2010; 73(3): 456–65.
27.
WangXChenGLiuHZhaoZLiZ. Four-dimensional orthogonal electrophoresis system for screening protein complexes and protein–protein interactions combined with mass spectrometry. J Proteome Res2010; 9(10): 5325–34.
28.
De PalmaARoveriAZaccarinM. Extraction methods of red blood cell membrane proteins for multidimensional protein identification technology (MudPIT) analysis. J Chromatogr A2010; 1217(33): 5328–36.
29.
PesciottaENSriswasdiSTangHMasonPJBesslerMSpeicherDW. A label-free proteome analysis strategy for identifying quantitative changes in erythrocyte membranes induced by red cell disorders. J Proteomics2012; 76(5): 194–202.
30.
FlorensLLiuXWangY. Proteomics approach reveals novel proteins on the surface of malaria-infected erythrocytes. Mol Biochem Parasitol2004; 135(1): 1–11.
KussCGanCSGunalanKBozdechZSzeSKPreiserPR. Quantitative proteomics reveals new insights into erythrocyte invasion by Plasmodium falciparum. Mol Cell Proteomics2012; 11(2): 1–14.
33.
LasonderETreeckMAlamMTobinAB. Insights into the Plasmodium falciparum schizont phospho-proteome. Microb Infect2012; 14(10): 811–9.
34.
MéndezDHernáezMLKamaliANDiezAPuyetABautistaJM. Differential carbonylation of cytoskeletal proteins in blood group O erythrocytes: Potential role in protection against severe malaria. Infect Genet Evol2012; 12(8): 1780–7.
35.
MillhollandMGChandramohanadasRPizzarroA. The malaria parasite progressively dismantles the host erythrocyte cytoskeleton for efficient egress. Mol Cell Proteomics2011; 10(12): 1–12.
36.
WuYNelsonMMQuaileAXiaDWastlingJMCraigA. Identification of phosphorylated proteins in erythrocytes infected by the human malaria parasite Plasmodium falciparum. Malaria J2009; 8(1): 105–105.
37.
DemiralpDOPekerSTurgutBAkarN. Comprehensive identification of erythrocyte membrane protein deficiency by 2D gel electrophoresis based proteomic analysis in hereditary elliptocytosis and spherocytosis. Proteomics – Clin Appl2012; 6(7–8): 403–11.
38.
PekerSAkarNDemiralpDO. Proteomic identification of erythrocyte membrane protein deficiency in hereditary spherocytosis. Mol Biol Rep2012; 39(3): 3161–7.
39.
SahaSRamanathanRBasuABanerjeeDChakrabartiA. Elevated levels of redox regulators, membrane-bound globin chains, and cytoskeletal protein fragments in hereditary spherocytosis erythrocyte proteome. Eur J Haematol2011; 87(3): 259–66.
40.
von LöhneysenKScottTMSoldauKXuXFriedmanJS. Assessment of the red cell proteome of young patients with unexplained hemolytic anemia by two-dimensional differential in-gel electrophoresis (DIGE). PLoS ONE2012; 7(4): e34237–e34237.
BhattacharyaDSahaSBasuS. Differential regulation of redox proteins and chaperones in HbEβ-thalassemia erythrocyte proteome. Proteomics – Clin Appl2010; 4(5): 480–8.
43.
ChakrabartiABhattacharyaDBasuABasuSSahaSHalderS. Differential expression of red cell proteins in hemoglobinopathy. Proteomics – Clin Appl2011; 5(1–2): 98–108.
44.
BlasiBD'AlessandroARamundoNZollaL. Red blood cell storage and cell morphology. Transfus Med2012; 22(2): 90–6.
45.
BosmanGJCGMLasonderEGroenen-DöppYAMWillekensFLAWerreJM. The proteome of erythrocyte-derived microparticles from plasma: New clues for erythrocyte aging and vesiculation. J Proteomics2012; 76: 203–10.
46.
CluitmansJCAHardemanMRDinklaSBrockRBosmanGJCGM. Red blood cell deformability during storage: Towards functional proteomics and metabolomics in the blood bank. Blood Transfus2012; 10(Suppl. 2): s8–14.
47.
DinklaSNovotnýVMJJoostenIBosmanGJCGM. Storage-induced changes in erythrocyte membrane proteins promote recognition by autoantibodies. PLoS ONE2012; 7(8): e42250–e42250.
48.
MohantyJGShuklaHDWilliamsonJDLaunerLJSaxenaSRifkindJM. Alterations in the red blood cell membrane proteome in Alzheimer's subjects reflect disease-related changes and provide insight into altered cell morphology. Proteome Sci2010; 8: 11–11.
49.
HuangJTWangLPrabakaranS. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatr2008; 13(12): 1118–28.
50.
PrabakaranSWengenrothMLockstoneHELilleyKLewekeFMBahnS. 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res2007; 6(1): 141–9.
51.
SunJJiaPFanousAH. Schizophrenia gene networks and pathways and their applications for novel candidate gene selection. PLoS ONE2010; 5(6): e11351–e11351.
52.
AlexandreBMCharroNBlonderJ. Profiling the erythrocyte membrane proteome isolated from patients diagnosed with chronic obstructive pulmonary disease. J Proteomics2012; 76: 259–269.
53.
Alvarez-LlamasGZubiriIMarotoAS. A role for the membrane proteome in human chronic kidney disease erythrocytes. Translat Res2012; 160(5): 374–83.
54.
JiangMJiaLJiangW. Protein dysregulation in red blood cell membranes of type 2 diabetic patients. Biochem Biophys Res Commun2003; 309(1): 196–200.
55.
ZhangQMonroeMESchepmoesAA. Comprehensive identification of glycated peptides and their glycation motifs in plasma and erythrocytes of control and diabetic subjects. J Proteome Res2011; 10(7): 3076–88.
56.
YuditskayaSSuffrediniAFKatoGJ. The proteome of sickle cell disease: Insights from exploratory proteomic profiling. Expert Rev Proteomics2010; 7(6): 833–48.
57.
ShartavaAMonteiroCAAladar BencsathF. A posttranslational modification of β-actin contributes to the slow dissociation of the spectrin-protein 4.1-actin complex of irreversibly sickled cells. J Cell Biol1995; 128(5): 805–18.
58.
ShartavaAMirandaPWilliamsKNShahAMonteiroCAGoodmanSR. High density sickle cell erythrocyte core membrane skeletons demonstrate slow temperature dependent dissociation. Am J Hematol1996; 51(3): 214–9.
BencsathFAShartavaAMonteiroCAGoodmanSR. Identification of the disulfide-linked peptide in irreversibly sickled cell β-actin. Biochemistry (New York)1996; 35(14): 4403–8.
61.
MonteiroCAGibsonXShartavaAGoodmanSR. Preliminary characterization of a structural defect in homozygous sickled cell alpha spectrin demonstrated by a rabbit autoantibody. Am J Hematol1998; 58(3): 200–5.
62.
GhatpandeSSGoodmanSR. Ubiquitination of spectrin regulates the erythrocyte spectrin-protein-4.1-actin ternary complex dissociation: Implications for the sickle cell membrane skeleton. Cell Mol Biol (Noisy-le-grand)2004; 50(1): 67–74.
63.
MishraRGoodmanSR. Ubiquitination of erythrocyte spectrin regulates the dissociation of the spectrin-adducin-f-actin ternary complex in vitro. Cell Mol Biol (Noisy-le-grand)2004; 50(1): 75–80.
64.
RiahiMHKakhniashviliDGGoodmanSR. Ubiquitination of red blood cell α-spectrin does not affect heterodimer formation. Am J Hematol2005; 78(4): 281–7.
65.
ChangTKakhniashviliDGGoodmanSR. Spectrin’s E2/E3 ubiquitin conjugating/ligating activity is diminished in sickle cells. Am J Hematol2005; 79(2): 89–96.
66.
KakhniashviliDGChaudharyTZimmerWEAladar BencsathFJardineIGoodmanSR. Erythrocyte spectrin is an E2 ubiquitin conjugating enzyme. Biochemistry (New York)2001; 40(38): 11630–42.
67.
ChangTLCubillosFFKakhniashviliDGGoodmanSR. Ankyrin is a target of spectrin's E2/E3 ubiquitin-conjugating/ligating activity. Cell Mol Biol (Noisy-le-grand)2004; 50(1): 59–66.
68.
ChangTLCubillosiFFKakhniashviliDGGoodmanSR. Band 3 is a target protein of spectrin's E2/E3 activity: Implication for sickle cell disease and normal red blood cell aging. Cell Mol Biol (Noisy-le-grand)2004; 50(2): 171–7.
HsuYJGoodmanSR. Spectrin and ubiquitination: A review. Cell Mol Biol (Noisy-le-grand)2005, (Suppl 51OL801–807.
71.
GoodmanSR. The irreversibly sickled cell: A perspective. Cell Mol Biol (Noisy-le-grand)2004; 50(1): 53–8.
72.
GibsonXAShartavaAMcIntyreJ. The efficacy of reducing agents or antioxidants in blocking the formation of dense cells and irreversibly sickled cells in vitro. Blood1998; 91(11): 4373–8.
73.
PaceBSShartavaAPack-MabienAMulekarMArdiaAGoodmanSR. Effects of N-acetylcysteine on dense cell formation in sickle cell disease. Am J Hematol2003; 73(1): 26–36.
74.
KakhniashviliDGGrikoNBBullaJr. LA, Goodman SR. The proteomics of sickle cell disease: Profiling of erythrocyte membrane proteins by 2D‐DIGE and tandem mass spectrometry. Exp Biol Med2005; 230(11): 787–92.
75.
ChouJChoudharyPKGoodmanSR. Protein profiling of sickle cell versus control rbc core membrane skeletons by icat technology and tandem mass spectrometry. Cell Mol Biol Lett2006; 11(3): 326–37.
76.
Hryniewicz-JankowskaAChoudharyPKGoodmanSR. Variation in the monocyte proteome. Exp Biol Med2007; 232(7): 967–76.
77.
Hryniewicz-JankowskaAChoudharyPKAmmannLPQuinnCTGoodmanSR. Monocyte protein signatures of disease severity in sickle cell anemia. Exp Biol Med2009; 234(2): 210–21.
78.
GhatpandeSSChoudharyPKQuinnCTGoodmanSR. Pharmaco-proteomic study of hydroxyurea-induced modifications in the sickle red blood cell membrane proteome. Exp Biol Med2008; 233(12): 1510–7.
79.
GhatpandeSSChoudharyPKQuinnCTGoodmanSR. In vivo pharmaco-proteomic analysis of hydroxyurea induced changes in the sickle red blood cell membrane proteome. J Proteomics2010; 73(3): 619–26.
80.
Kurdia A, Daescu O, Ammann L, Kakhniashvili D, Goodman SR. Centrality measures for the human red blood cell interactome. Engineering in Medicine and Biology Workshop, IEEE Dallas, 2007:98–101.
81.
AmmannLPGoodmanSR. Cluster analysis for the impact of sickle cell disease on the human erythrocyte protein interactome. Exp Biol Med2009; 234(6): 703–11.
82.
ZivanicMDaescuOKurdiaAGoodmanSR. The Voronoi diagram for graphs and its application in the sickle cell disease research. J Comput Sci2012; 3(5): 335–43.
83.
ErwigM. Graph Voronoi diagram with applications. Networks2000; 36(3): 156–63.
84.
BendallSCNolanGP. From single cells to deep phenotypes in cancer. Nat Biotechnol2012; 30(7): 639–47.
85.
BodenmillerBZunderERFinckR. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol2012; 30(9): 858–67.
de VriesSJBonvinAMJJ. Cport: A consensus interface predictor and its performance in prediction-driven docking with HADDOCK. PLoS ONE2011; 6(3): e17695–e17695.
88.
HennigJde VriesSHennigKDM. MTMDAT-HADDOCK: High-throughput, protein complex structure modeling based on limited proteolysis and mass spectrometry. BMC Struct Biol2012; 29.
89.
KaracaEBonvinAMJJ. A multidomain flexible docking approach to deal with large conformational changes in the modeling of biomolecular complexes. Structure2011; 19(4): 555–65.
90.
MelquiondASKaracaEKastritisPLBonvinAM. Next challenges in protein-protein docking: From proteome to interactome and beyond. Wiley Interdis Rev: Comput Mol Sci2012; 2(4): 642–51.
WangXWeiXThijssenBDasJLipkinSMYuH. Three-dimensional reconstruction of protein networks provides insight into human genetic disease. Nat Biotechnol2012; 30(2): 159–64.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
